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ABSTRACT 
PURPOSE:  Excessive medical treatment at end-of-life is an indicator of poor quality 
care. While radiation therapy (RT) is effective for palliation, some patients die shortly 
after or even during treatment. Any treatment that requires terminal patients to 
spend significant time in the hospital setting contradicts palliative goals. This study 
investigates patterns of end-of-life RT to inform quality improvement initiatives. 
METHODS:  All patients who died within 6 months of starting RT at a single large 
academic cancer center between 2015 through 2018 were identified through our 
institutional databases on an Institutional Review Board-approved protocol. Clinical 
factors including age, treatment service, number of fractions, diagnosis, treatment 
site, and treatment date were evaluated for associations with endpoints, 30-day 
mortality and on-treatment mortality (mid-course), via logistic regression analysis. 
 
 
RESULTS: 1,855 patients died within 6 months of initiating RT at our center. Of 
these, 619 patients (33%) died within 30 days of starting RT, and were most 
commonly treated by thoracic (26%), CNS (21%), and hematologic (13%) services. 
Commonly treated sites included brain/spine (27%), bone (26%), and 
mediastinum/thorax (10%). On logistic regression, both extended radiotherapy 
prescription fractionation (>10 fractions/course) [OR 0.50, p<0.001] and advanced 
stereotactic treatment technique (OR 0.61, p=0.002) were associated with 
decreased likelihood of 30-day mortality, reflecting appropriate clinical rationale of 
treating providers. Neither age (≥70 vs. <70 years) [OR 0.93, p=0.538] nor treatment 
year (2017-2018 vs. 2015-2016) [OR 0.97, p=0.744] were associated with 30-day 
mortality. Of the 619 patients, 142 (23%) died midway before completion of RT 
course. Patients treated for emergent palliative mediastinal/thoracic indications (OR 
11.4, p<0.001) were more likely to die midway through RT than those treated for 
bone metastases. Notably, 2 out of every 3 patients treated for emergent palliative 
mediastinal/thoracic indications (e.g. airway obstruction, hemoptysis) died on-
treatment, comprising 27% of all on-treatment deaths (p<0.001). 
CONCLUSION:  Palliative RT remains an important therapeutic tool at the end-of-
life. However, careful consideration of RT for emergent mediastinal/thoracic 
indications should be used, given the high potential for on-treatment mortality. Taken 
together, these data may help inform physician decision-making and facilitate 
treatment consistent with palliative goals at the end-of-life. 
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BACKGROUND 
Literature Review 
Excessive medical treatment at the end-of-life is an indicator of poor quality care [1]. 
Radiation therapy is routinely used for both curative and palliative cancer treatment. 
Radiation can be an effective tool for palliation of symptoms arising from cancer, 
such as pain from bone metastases or neurologic compromise from brain or spinal 
metastases. 
Although radiation is often well-tolerated with good outcomes, regardless of 
goals of therapy, there are some patients that die soon after or even during 
treatment. Furthermore, any treatment that requires dying patients to spend a 
significant proportion of their final days in a hospital is contrary to the overall aims of 
palliative care. 
Nationwide, it is estimated that the majority of overall healthcare costs may be 
attributed to care for patients within their last year of life [1-3]. Contributing to this 
empirical pattern is the statistic that 1 in 5 patients who received radiation in their 
final 30 days of life spend more than 10 of those days receiving treatment [1]. In 
addition, among these patients, there has been a shift towards more advanced 
radiation technologies, away from simpler (and most cost-effective) techniques [2-3].  
These factors contribute to the finding that the costs of care for patients who 
received radiotherapy at the end of life are higher than for those patients who did not 
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[1]. Taken altogether, there is a need for quality improvement initiatives related to 
palliative radiation delivered at the end-of-life. 
 
Public Health Significance 
As previously mentioned, there is a need for additional research into appropriate 
indications for radiation at the end-of-life, to facilitate physician decision-making 
regarding use of radiation consistent with palliative goals for patients with end-stage 
cancer. For example, clinical guidelines could help oncologists reconsider treatment 
or offer shorter (lower cost) treatment courses for uncomplicated cases while still 
maintaining quality-of-life for such patients. 
From a healthcare value framework, by defining indications for palliative 
radiation (and reducing utilization in these scenarios), such guidelines would 
promote the Institute for Healthcare Improvement (IHI) quality dimensions of 
effectiveness, patient-centeredness, and safety (as some patients may have 
hastened death due to excessive treatment courses). Furthermore, these guidelines 
would be disseminated via publication to promote quality improvement on a national 
population level. 
 
Specific Research Aims and Objectives 
In this study, we are first interested in quantitatively analyzing our collective 
experience (as the largest national cancer center) in treating patients to identify any 
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predictors of mortality in patients that are treated with radiation therapy, so that we 
can better select optimal treatments in the future and provide quality care. Data from 
this initial quantitative analysis will then be applied towards the following aims and 
objectives related to the field of public health, which require a more comprehensive 
interpretation in the context of the current literature: 
 
1. By identifying recurring themes in these cases (particularly for patients who die 
in-hospital away from their homes midway through treatment), these findings 
would serve as a sort of immediate quality improvement initiative for our 
Department of Radiation Oncology-- to communicate appropriate indications to 
our 70 Radiation Oncology attending providers on the frontlines of oncological 
care, defining those specific settings in which they should exercise particular 
caution in deciding whether or not to offer treatment. With such guidelines, we 
would expect to see these on-treatment mortality rates decrease (as well as the 
overall numbers of patients getting aggressive treatments at the end-of-life). 
 
2. We would then communicate these guidelines/criteria via publication, for 
other providers across the country to refer to and apply within their Departments, 
in an effort to improve healthcare quality on a national population level. 
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3. Finally, we will interpret these findings from the perspective of a healthcare 
value framework. If these treatments are prescribed gratuitously, they provide 
questionable benefit in terms of patient comfort and quality-of-life. Furthermore, 
they are associated with sometimes high absolute healthcare costs to the 
patient/payer and provider, making them relatively low-value treatments. 
Although cost-specific analyses are beyond the scope of this study, by defining 
less-than-appropriate indications for palliative radiation (and reduce utilization in 
these scenarios), we would promote the IHI healthcare quality dimensions of 
effectiveness, patient-centeredness, and even safety (as some patients may 
have hastened death due to "aggressive" treatment courses).  
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METHODS 
Study Design 
In the initial quantitative data-generation portion of this study, the hospital and 
radiation therapy charts of individual patients treated with radiation therapy (with 
both curative and palliative intent) were reviewed and correlated to time of death.  
Patients who died within 6 months of starting radiation therapy, including those 
treated with definitive (curative) intent and those undergoing palliative treatment 
were identified through the institutional database.   
Once the cohort was established, individual clinical variables (e.g. age, 
diagnosis, treatment site, hospitalization status, etc.) were analyzed and used to 
determine if there was an ability to predict mortality during or after radiation therapy, 
as per the statistical methods outlined in detail below. 
Data from this initial quantitative analysis are being applied towards a more 
comprehensive review of the data to address the aforementioned research aims and 
objectives related to public health. Most notably, we will summarize our findings and 
establish clinical guidelines for other practitioners to improve healthcare quality in 
the palliative end-of-life setting at a national population level. Furthermore, we will 
perform a detailed review and interpret these findings from the perspective of a 
healthcare value framework within the setting of the current relevant literature. 
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Study Setting 
Department of Radiation Oncology at the University of Texas MD Anderson Cancer 
Center (Houston, Texas) 
 
Study Subjects 
Patients treated at MD Anderson with radiation therapy from January 1, 2010 to 
November 30, 2018 were included. All patients who received treatment and died 
within 6 months of starting radiation, including patients treated with definitive 
(curative) intent and patients who received palliative treatment, were included in the 
analysis. 
 
Sample Size Calculation and/or Study Power 
There was no formally calculated sample size given the retrospective nature of this 
review.  We sought to capture the overall experience of treated patients at our 
institution. However, initial review of the total dataset indicated that several hundred 
patients met the eligibility criteria within the wide timeframe and were included in the 
analysis. Despite its retrospective nature, these patient numbers increased the 
likelihood of finding meaningful and statistically-significant findings.  
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Data Collection 
This study was IRB-approved by the University of Texas MD Anderson Cancer 
Center (PA15-0639). For each identified patient, a retrospective chart review was 
conducted within the electronic medical records (EPIC/OneConnect and 
ClinicStation) for various clinical variables and mortality.  
 
Data Analysis 
Once the cohort was established, individual clinical variables (e.g. age, race, 
diagnosis, treatment site, hospitalization status, etc.) were analyzed and used to 
determine if there was an ability to predict mortality during or after radiation therapy. 
Regarding statistical analyses, we applied logistic regression techniques to 
determine the factors that predispose to mortality after radiation therapy via 
associations of outcome to patient and treatment characteristics.  These data can 
help guide clinical practice guidelines which will be developed following review of the 
data by an expert provider panel including the principal investigator. 
 
Human Subjects and Safety Considerations   
This protocol is a retrospective study which was IRB-approved by the University of 
Texas MD Anderson Cancer Center (PA15-0639), including approval of a waiver of 
informed consent, given the retrospective nature of this project. This protocol was 
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also approved by the University of Texas Health Science Center Committee for 
Protection of Human Subjects (HSC-SPH-18-1068). 
Patient confidentiality was strictly maintained. The research involved no more 
than minimal risk to the study subjects (i.e. risk of accidental release of personal and 
or confidential information) because the patient history and treatment details of these 
deceased patients were gathered from the hospital records. The waiver or alteration 
did not adversely affect the rights, welfare, or subsequent clinical management. This 
research could not practically be carried out without the waiver or alteration, given 
that study subjects are deceased. 
Cases were coded by anonymous study number using a key kept separate 
from the database.  Only the principal investigator of this study had access to patient 
information, and only information relevant to this protocol was examined. All 
protected health information was de-identified prior to releasing outcomes of the 
study outside the research team. Strict patient confidentiality was maintained.  
Data was stored on a password and firewall protected computer. A study 
identifier was assigned to each case. A separate file containing the identifier and 
subject names/MRN was maintained. Data was presented in aggregate.  Data was 
solely available to the principal investigator working on the project and kept on a 
password-protected hard-drive with no patient specific information. 
There are no paper records of data with personal identifiers. Patient identifiers 
will be destroyed within 5 years of study completion.  Until then, the database will be 
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password protected on a limited access computer. Information will be destroyed 
within 5 years after study publication. 
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ABSTRACT 
PURPOSE:  Excessive medical treatment at end-of-life is an indicator of poor-quality 
care. While radiation therapy (RT) is effective for palliation, some patients die shortly 
after or even during treatment. Any treatment requiring terminal patients to spend 
significant time in the hospital contradicts palliative goals. This study investigates 
patterns of end-of-life RT at our institution to inform practice guidelines and quality 
improvement initiatives. 
MATERIALS AND METHODS:  All patients who died within 6 months of starting RT 
at our large academic cancer center between 2015 through 2018 were identified. 
Clinical factors including age, diagnosis, inpatient status, number of fractions, 
treatment date, service, and site were evaluated for associations with endpoints, 30-
day mortality and on-treatment (mid-course) mortality, via logistic regression. 
RESULTS: A total of 1,855 patients died within 6 months of initiating RT. Of these, 
619 died within 30 days, and were most commonly treated by thoracic (26%), CNS 
(21%), and hematologic (13%) services. Commonly treated sites included 
brain/spine (27%), bone (26%), and mediastinum/thorax (10%). Both extended 
fractionation (>10/course) [OR 0.50, p<0.001] and stereotactic technique (OR 0.61, 
p=0.002) were associated with decreased 30-day mortality, reflecting clinical 
rationale of providers. Neither age (≥70 vs. <70 years) [p=0.538] nor treatment year 
(2017-2018 vs. 2015-2016) [p=0.744] were associated with 30-day mortality. Of 619 
patients, 142 (23%) died mid-course before completion. Patients treated for 
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emergent mediastinal/thoracic indications (OR 11.4, p<0.001) were more likely to die 
mid-course than those treated for bone metastases. Notably, 2 of every 3 patients 
treated for emergent mediastinal/thoracic indications died on-treatment, comprising 
27% of on-treatment deaths (p<0.001). 
CONCLUSION:  Palliative RT remains an important therapeutic tool at the end-of-
life. However, careful consideration of RT for emergent mediastinal/thoracic 
indications should be used, given high potential for on-treatment mortality. Taken 
together, these data help inform physician decision-making and facilitate treatment 
consistent with palliative goals. 
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INTRODUCTION 
Radiation therapy is an effective tool for palliation of symptoms arising from 
cancer—such as pain from bone metastases [1,2], neurologic compromise from 
spine or brain metastases [3], or bleeding from tumors [4]—and thus serves as an 
important mainstay of end-of-life oncologic care. However, while RT is effective for 
palliation, some patients may die during treatment, or too shortly afterwards to 
realize palliative benefit; and any therapy requiring terminal patients to spend 
significant time in the hospital contradicts palliative goals. 
 Excessive medical treatment at the end-of-life is an indicator of poor-quality 
care [5,6], yet many patients continue to receive aggressive treatment in their last 
days [7,8]. Along these lines, recent practice patterns for palliative RT have been 
examined with scrutiny due to concerns for overutilization. An estimated 1 in 5 
patients who receive RT in their final 30 days of life will spend >10 of those days 
receiving treatment [5]; and among these patients, there has also been a shift 
towards more advanced RT technologies, away from simpler (and more cost-
effective) techniques [9,10]. 
 Much of this overutilization likely stems from the difficulty of accurately 
predicting life expectancies for terminally ill patients. Physicians tend to misjudge 
patient survival times [11–16], which can lead to overtreatment or extended 
treatment courses disproportionate to patient life expectancies. Taken together, 
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these practice trends call for more data to facilitate physician decision-making at the 
end-of-life and improve the quality of palliative RT. 
To help address this literature void, our study investigates the patterns of on-
treatment and early post-treatment mortality for palliative RT at our large academic 
cancer center. This investigation is the largest of its kind to date—encompassing all 
tumor histologies, disease sites, and palliative indications—and thus improves upon 
limited prior reports [17–19]. In addition to describing these patterns, we evaluate 
specific clinical factors associated with early post-treatment and on-treatment 
mortality, to inform subsequent practice guidelines and quality improvement 
initiatives. 
 
MATERIALS AND METHODS 
Design, Patient Population, and Data Sources 
All patients who died within 6 months of starting RT at a single large academic 
cancer center between January 1, 2015 through December 31, 2018 were identified 
through our institutional databases. Various clinical factors including age, treatment 
service, number of fractions, diagnosis, treatment site, indication, inpatient status, 
and treatment date were collected. This study protocol was approved by the 
Institutional Review Board at the University of Texas MD Anderson Cancer Center 
(PA15-0639). 
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Statistical Analyses 
The primary endpoints were on-treatment (mid-course) mortality and 30-day (early) 
post-treatment mortality (computed from the start of RT). Univariate and 
multivariable logistic regression analyses were conducted to identify potential 
associations between clinical or treatment variables and mortality endpoints, 
generating odds ratios (ORs) and 95% confidence intervals (CIs). Statistical 
analyses were performed in SPSS version 23 (IBM Corp, release 2015; IBM SPSS 
Statistics for Windows, Version 23.0; Armonk, NY: IBM Corp). For all statistical tests, 
a p-value <0.05 was considered significant. 
 
RESULTS 
Patient and Treatment Characteristics 
A total of 1,855 patients died within 6 months of initiating RT at our center. Of these, 
619 patients (33%) died within 30 days of starting RT, and were most commonly 
treated by thoracic (26%), CNS (21%), and hematologic (13%) services. Commonly 
treated sites included brain/spine (27%), bone (26%), and mediastinum/thorax 
(10%). Roughly 20% of hematologic patients were stem cell transplant candidates. 
 
Factors Associated with Mortality within 30 Days of RT 
On logistic regression, both extended radiotherapy prescription fractionation (>10 
fractions/course) [OR 0.50, p<0.001] and advanced stereotactic treatment technique 
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(OR 0.61, p=0.002) were associated with decreased likelihood of 30-day mortality, 
reflecting appropriate clinical rationale of treating providers. Neither age (≥70 vs. <70 
years) [OR 0.93, p=0.538] nor treatment year (2017-2018 vs. 2015-2016) [OR 0.97, 
p=0.744] were associated with 30-day mortality. 
 
Factors Associated with On-Treatment Mortality During RT 
Of the 619 patients, 142 (23%) died midway before completion of RT course. 
Patients treated for emergent palliative mediastinal/thoracic indications (OR 11.4, 
p<0.001) were more likely to die midway through RT than those treated for bone 
metastases. Notably, 2 out of every 3 patients treated for emergent palliative 
mediastinal/thoracic indications (e.g. airway obstruction, hemoptysis) died on-
treatment, comprising 27% of all on-treatment deaths (p<0.001). Of note, 80% of all 
patients who died on-treatment were inpatients, while 82% of the 
thoracic/mediastinum patients were inpatient. 
 
DISCUSSION 
In this study investigating patterns of mid-treatment and early post-treatment 
mortality in palliative RT, our pertinent findings were as follows: (a) out of all patients 
who died within 6 months of initiating RT at our institution, one-third died within the 
first 30 days following RT, and a quarter of those patients died on-treatment; (b) 
inpatient status was significantly associated with mid-course mortality, with 80% of 
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on-treatment deaths occurring in hospitalized patients; and finally (c) patients treated 
for emergent mediastinal/thoracic indications were more likely to die on treatment, 
with 2 of every 3 patients dying before completion of RT. 
 The high proportion of patients dying shortly after or even during palliative RT 
at our institution is consistent with prior reports of RT utilization at the end-of-life 
[5,17]. This discrepancy likely stems from provider tendency to overestimate survival 
times for terminally ill patients, which leads to difficulty in tailoring palliative regimens 
appropriately to limited life expectancies [11–16]. As such, these data call for 
additional efforts focused on improving life expectancy assessments. Reassuringly, 
our study demonstrated lower utilization of extended fraction prescriptions (>10 
fractions/course) and advanced stereotactic techniques in patients who died within 
30 days of RT. This finding is consistent with the ASTRO Choosing Wisely 
guidelines for end-of-life treatment, which advocate for shorter palliative courses for 
patients with limited prognoses, as multiple studies have demonstrated the non-
inferiority of shorter regimens [2,20,21]. 
 With regard to clinical prognostic factors, inpatient hospitalization status 
during RT was significantly associated with on-treatment mortality among our patient 
population. This finding is corroborated by prior reports of palliative RT which 
demonstrate worse survival outcomes for patients evaluated as inpatient consults 
[17,22], and for those with advanced disease experiencing an unplanned admission 
for symptom control [18] or an intensive care unit admission [19]. Similarly, Grade et 
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al. similarly demonstrated higher rates of stopping treatment early among inpatients 
[18]. Taken together, these data support inpatient RT as a clinical prompt for 
comprehensive palliative care and hospice referral, if not already present. Shorter 
hypo-fractionated treatment courses are also preferred in this setting, given the poor 
performance statuses and prognoses of such inpatients. 
 In addition to inpatient status, our study found emergent mediastinal/thoracic 
indications to be highly associated with on-treatment mortality, with 2 out of every 3 
patients dying before completion of RT. In general, many patients with metastatic or 
incurable locally advanced lung cancers can benefit from palliative thoracic RT to 
alleviate tumor-related symptoms such as hemoptysis, cough, and chest pain [23–
26]; and even high-dose rate endobronchial brachytherapy is efficacious for 
palliating airway obstruction or hemoptysis due to endobronchial tumors [25,27]. 
However, our data indicate that the majority of emergent mediastinal/thoracic cases 
(e.g. severe hemoptysis or bronchial obstruction in the inpatient setting) are likely to 
die mid-treatment prior to RT completion. These findings are consistent with those of 
Grade et al., who demonstrated airway compromise as a serious indication 
associated with worse survival [18]. Therefore, while palliative RT can be safe and 
efficacious for a range of thoracic indications, providers should exercise caution for 
emergent mediastinal/thoracic cases, given the high likelihood of on-treatment 
mortality in this setting. 
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 To summarize, this study analyzes the patterns of on-treatment and early 
post-treatment mortality of patients undergoing palliative RT at a large academic 
cancer center. The major limitation of this work is its single-institution, retrospective 
nature, reflecting practice patterns specific to our provider group. However, our study 
benefits from being the largest series of its kind to date and encompassing a wide 
range of palliative indications and sites, thereby improving upon previous reports 
[17–19]. Taken together, these data can inform practice guidelines and quality 
improvement initiatives aimed at optimizing end-of-life care for terminally-ill patients 
with cancer. 
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CONCLUSION 
To summarize, this study analyzes the patterns of on-treatment and early post-
treatment mortality of patients undergoing palliative RT at a large academic cancer 
center. Palliative RT remains an important therapeutic tool at the end-of-life. 
However, careful consideration of RT for emergent mediastinal/thoracic indications 
should be used, given the high potential for on-treatment mortality. Taken together, 
these data may help inform physician decision-making and facilitate treatment 
consistent with palliative goals at the end-of-life. 
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